Back to School
Standards of evidence for accelerated approval: a BioCentury Back to School podcast
The complexities of creating an approvable data package for accelerated approval
BioCentury’s editors analyze the complexities of creating an approvable data package for accelerated approval and assess emerging surrogate endpoints.
In the second of four podcasts discussing this year’s Back to School package, BioCentury’s editors discuss the complexities of creating an approvable data package for accelerated approval as well as emerging surrogate endpoints.
On the first Back to School podcast, BioCentury’s editors assessed the opportunities and challenges of accelerated approval and what the future looks like for the pathway.
In Tuesday’s discussion, the editors home in on the standards of evidence required for an accelerated or conditional approval.
“We’ve looked at this from the angle that accelerated and conditional approval pathways should actually be a springboard for innovation and in the stretch vision that would mean you need to create many novel surrogate endpoints to enable the use of the pathways in more indications and more diseases,” says BioCentury Editor in Chief Simone Fishburn.
In the U.S., FDA can grant accelerated approval, if a therapy meets a surrogate endpoint that is deemed “reasonably likely” to predict clinical benefit.
“The problem is there’s no real standard for what ‘reasonably likely’ means,” Fishburn says.
The goal should be a “rational standard that’s reliable and applied routinely,” says Executive Editor Selina Koch, adding that a regulatory agency could use different standards for different diseases or mechanisms of action.